Clinical Trial Update: Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AZD5069 in patients with bronchiectasis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchiectasis, Lung Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-10-08